Elanco Animal Health Inc (N:ELAN)

Business Focus: Veterinary Drugs

Sep 05, 2019 05:00 pm ET
Elanco to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
Elanco Animal Health, Inc. (NYSE: ELAN) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, Sept. 11, 2019, in New York. Jeff Simmons, Elanco president and chief executive officer, will participate in a fireside chat at 8:45 a.m. Eastern Time.
Aug 20, 2019 05:30 am ET
Elanco Announces Agreement to Acquire Bayer’s Animal Health Business
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with Bayer AG (ETR: BAYN) to acquire its animal health business in a transaction valued at US$7.6 billion. The transaction, which is subject to regulatory approval and other customary closing conditions, creates the second largest animal health leader while strengthening and accelerating the company’s proven Innovation, Portfolio and Productivity (IPP) strategy.
Aug 13, 2019 06:30 am ET
Elanco Animal Health Reports Second Quarter Results, Including Strong EPS and Gross Margin Improvement
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2019. The results reflect underlying price and volume growth, and improved profitability through execution of the company's targeted, three-pillar strategy focused on Innovation, Portfolio and Productivity (IPP).
Aug 01, 2019 06:30 am ET
Elanco Announces Acquisition of Prevtec Microbia Swine Vaccine Company
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the acquisition of Montreal-based Prevtec Microbia Inc. (Prevtec), a biotechnology startup specializing in the development of vaccines that help prevent bacterial diseases in food animals.
Jul 18, 2019 08:31 am ET
Elanco Finalizes Acquisition of Aratana Therapeutics
Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®.
Jun 27, 2019 06:30 am ET
Elanco Announces R&D Collaboration with AgBiome for Swine Nutritional Health Innovation
Elanco Animal Health Incorporated (NYSE: ELAN), announced today a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine. The collaboration further demonstrates Elanco’s commitment to antibiotic stewardship and bringing alternatives to producers’ most difficult challenges.
May 21, 2019 07:00 am ET
New Study Suggests Service Dogs Can Impact Psychosocial Health of Household
New data published in The American Journal of Occupational Therapy suggests the impact of a service dog may extend beyond the recipient and have positive impacts on family members as well.
May 09, 2019 06:29 am ET
Elanco Animal Health Reports First Quarter Results
Elanco Animal Health Incorporated (NYSE: ELAN), today reported its financial results for the first quarter of 2019. The results reflect underlying volume growth and execution of the company's targeted, three-pillar strategy focused on Innovation, Portfolio and Productivity.
May 08, 2019 04:15 pm ET
Elanco Appoints Art A. Garcia to Board of Directors
Elanco Animal Health (NYSE: ELAN) today announced the appointment of Art A. Garcia, recently retired executive vice president and chief financial officer of Ryder System Inc., to the Board of Directors. The board was established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company.
Apr 30, 2019 12:21 pm ET
MERGER ALERT – PETX and SRMC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Aratana Therapeutics, Inc. (NASDAQGM: PETX)...
Apr 29, 2019 05:28 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Aratana Therapeutics, Inc. (PETX) on Behalf of Stockholders and Encourages PETX Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX) on behalf of stockholders concerning the proposed merger with Elanco Animal Health (NYSE: ELAN). Click here...
Apr 29, 2019 03:30 pm ET
Elanco Confirms Date and Conference Call for First Quarter 2019 Financial Results Announcement
Elanco Animal Health (NYSE: ELAN) will announce its first quarter 2019 financial results on Thursday, May 9, 2019. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Apr 29, 2019 01:00 pm ET
QTNA, PETX, and SFS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Quantenna Communications, Inc. (NYSE: QTNA) regarding possible breaches of fiduciary duties and other violations of law related to Quantenna’s agreement to be acquired by ON...
Apr 29, 2019 10:10 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Aratana Therapeutics, Inc. to Elanco Animal Health Incorporated is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (NASDAQGM: PETX) stock prior to April 26, 2019. You are hereby notified that...
Apr 26, 2019 02:25 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics, Inc.
NEW YORK, April 26, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Aratana Therapeutics, Inc. (NASDAQ: PETX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Elanco Animal Health Incorporated (NYSE: ELAN). Stockholders will receive 0.1481 shares of Elanco Animal Health common stock and one contingent value right valued at $0.25 for each share of Aratana Therapeutics stock that they hold. The transaction is valued at approximately $245 million....
Apr 26, 2019 06:29 am ET
Elanco Announces Agreement to Acquire Aratana Therapeutics; Completes Oncology Development Agreement with VetDC, Creates Specialty Veterinary Business Focus
Elanco Animal Health (NYSE:ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (NASDAQ:PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. Elanco has also signed a development and commercialization agreement with VetDC for Tanovea®-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.
Apr 26, 2019 06:28 am ET
Aratana Therapeutics to be Acquired by Elanco Animal Health
LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. Aratana's field force has demonstrated the ability to technically communicate with veterinarians on p...
Apr 09, 2019 08:45 am ET
Investor Expectations to Drive Momentum within Dermira, Elanco Animal Health, Ready Capital, Cushman & Wakefield, BlueLinx, and Lydall — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Dermira, Inc. (NASDAQ:DERM), Elanco Animal Health Incorporated (NYSE:ELAN),...
Mar 13, 2019 08:00 am ET
Lilly Announces Final Results of Elanco Exchange Offer
INDIANAPOLIS, March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) previously owned by Lilly, which expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019....
Mar 13, 2019 06:30 am ET
Elanco Appoints Four New Members to Board of Directors
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of four new members to the Board of Directors. The new members will serve on staggered terms, creating a nine-member Board. The Board was initially established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company. The appointments follow Lilly’s full divestiture of Elanco, making Elanco a fully independent company.
Mar 11, 2019 06:47 am ET
Elanco Animal Health Completes Separation from Lilly
Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it is now a fully independent company. The completion of Eli Lilly and Company’s exchange offer completes the journey Elanco began in 2017 when its former parent company first announced the exploration of potential strategic alternatives for the 64-year-old animal health company. The exchange offer was 7.6x oversubscribed.
Mar 11, 2019 06:45 am ET
Lilly Announces Preliminary Results of Elanco Exchange Offer
INDIANAPOLIS, March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Under the terms of the exchange offer, 4.5121 shares of Elanco common stock will be exchanged for each share of Lilly common stock accepted in the exchange offer....
Mar 07, 2019 05:45 am ET
Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer
INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly....
Feb 08, 2019 07:45 am ET
Elanco Animal Health to File Registration Statement in Connection With Lilly Divestiture Announcement
Elanco Animal Health Incorporated (NYSE: ELAN), formerly the animal health business of Eli Lilly and Company (Lilly), today announced it intends to file a Form S-4 Registration Statement with the Securities and Exchange Commission (SEC) in connection with Lilly’s proposed exchange offer whereby Lilly shareholders can exchange shares of Lilly common stock for shares of Elanco common stock owned by Lilly. The exchange offer is anticipated to be tax-free for participating Lilly shareholders in the United States, except with respect to cash received
Feb 08, 2019 05:45 am ET
Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health
INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE: ELAN)....
Feb 06, 2019 06:25 am ET
Elanco Animal Health Reports Strong 2018 Fourth Quarter and Full Year Results, Confirms 2019 Guidance
Elanco Animal Health Incorporated (NYSE:ELAN), today reported global revenue for full year 2018 increased 6 percent to $3.1 billion. For the fourth quarter of 2018, global revenue also grew 6 percent to $799.3 million. The results reflect strong volume growth and the execution of the company’s targeted, three-pillar strategy focused on Portfolio, Innovation and Productivity. The results also reflect strong full year performance in its three targeted growth categories: Companion Animal Disease Prevention, Companion Animal Therapeutics and Food An
Jan 30, 2019 03:15 pm ET
Elanco Revises Date for Fourth Quarter 2018 Financial Results
Elanco Animal Health (NYSE: ELAN) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. The company will now announce results on Wednesday, Feb. 6, 2019, one week earlier than previously scheduled. Elanco will also conduct a conference call with the investment community and media on that day to further detail the company's financial performance.
Jan 28, 2019 07:00 am ET
Elanco Animal Health and Performance Livestock Analytics Establish Data Service Agreement
Performance Livestock Analytics, Inc. (PLA) and Elanco Animal Health Incorporated (NYSE: ELAN), today announce an agreement to provide joint customers data from PLA’s fast-growing Performance Beef TM platform and access to Elanco’s Benchmark ® service. This alliance is designed to deliver continuous, real-time data to help cattle producers optimize their practices and products, paving the way for improved profitability.
Dec 18, 2018 01:17 pm ET
Elanco Announces 2019 Financial Guidance
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its updated 2018 and initial 2019 financial guidance, including 2019 revenue expectations in the range of $3.10 billion to $3.16 billion.
Dec 04, 2018 07:02 am ET
Elanco Animal Health Confirms Date and Conference Call for 2019 Financial Guidance
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its financial guidance for 2019 on Tuesday, Dec. 18, 2018. Elanco will also conduct a conference call that day with the investment community to further detail the company's financial guidance.
Nov 29, 2018 02:00 am ET
Elanco Animal Health and Farm Radio International Partner to Drive Change for Small-Scale Livestock Farmers in North Tanzania
Elanco Animal Health Incorporated (NYSE:ELAN) and Farm Radio International (FRI) have partnered to produce a 13-week series of radio programs designed to support and educate small-scale livestock farmers in North Tanzania to manage the challenges around livestock health and wellbeing, supporting a drive to greater food security, livestock health and care in the region.
Nov 20, 2018 08:45 am ET
Investor Expectations to Drive Momentum within Richardson Electronics, Encore Wire, Elanco Animal Health, AAR, Cushman & Wakefield, and Emerald Expositions Events — Discovering Underlying Factors of I
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Richardson Electronics, Ltd. (NASDAQ:RELL), Encore Wire Corporation...
Nov 06, 2018 06:02 am ET
Elanco Animal Health Reports Strong Third Quarter Results, Provides Financial Guidance for Full Year 2018
Elanco Animal Health Incorporated (NYSE: ELAN), substantially all of the animal health business of Eli Lilly and Company (Lilly), today reported financial results for the third quarter of 2018, its first after completing a successful initial public offering during the quarter.
Nov 02, 2018 06:45 am ET
Elanco Announces Collaboration Agreement with Novozymes for Nutritional Health Innovation
Elanco Animal Health Incorporated (NYSE:ELAN), announced today a new global R&D collaboration with Novozymes A/S (OMX: NZYM B), the world leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally.
Oct 30, 2018 06:30 am ET
Elanco Names Todd S. Young as New Chief Financial Officer
Elanco Animal Health Incorporated (NYSE:ELAN), today named Todd S. Young as executive vice president and chief financial officer (CFO), joining Elanco’s Executive Committee and reporting to Elanco president and chief executive officer, Jeffrey N. Simmons.
Oct 16, 2018 06:45 am ET
Elanco Animal Health Works to Increase Food Security in East Africa
Elanco Animal Health Incorporated (NYSE:ELAN) is progressing a groundbreaking project to provide sustainable development solutions to address food insecurity in East African countries – Tanzania, Kenya and Uganda. The East Africa Growth Accelerator (EAGA) is Elanco’s first pure ‘Shared Value’ project, which is made possible through a $3.1 million grant from the Bill & Melinda Gates foundation. The grant enables the registration, manufacturing and distribution of affordable high-quality veterinary products, along with intensive training initiativ
Sep 25, 2018 01:00 pm ET
Elanco Animal Health Expands Commitment to Fight Antimicrobial Resistance
Elanco Animal Health (NYSE: ELAN) today updated its commitment to fighting antimicrobial resistance, which includes promoting responsible antibiotic use practices and policies while developing alternatives to medically important antibiotics (a subset of which include critically important antibiotics to human health). This latest move further refines Elanco’s aggressive, multifaceted 8-point plan announced in 2015 at the White House Stewardship Forum. Today’s commitments focus on three key areas of stewardship, including combating antimicrobial r
Sep 24, 2018 05:36 pm ET
Elanco Animal Health Incorporated Announces IPO Closing
Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering (“IPO”) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. In connection with the IPO, the underwriters exercised in full their option to purchase an additional 9.435 million shares of common stock at the price to the public less underwriting discounts, bringing the total IPO size to 72.335 million shares. The shares began trading on the New York Stock Exchange on September 20, 2018, under the ti
Sep 24, 2018 07:45 am ET
Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings
Elanco Animal Health Incorporated (NYSE:ELAN) announced the underwriters of its initial public offering (IPO) have fully exercised their option to purchase an additional 9.435 million shares at the initial public offering price of $24.00 per share, less underwriting discounts, bringing the total IPO size to 72.335 million shares.
Sep 19, 2018 05:12 pm ET
Elanco Announces Pricing of Initial Public Offering
Elanco Animal Health Incorporated, a subsidiary of Eli Lilly and Company (NYSE:LLY), announced today the pricing of its initial public offering (IPO) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. The shares are expected to begin trading on the New York Stock Exchange (NYSE) on September 20, 2018 under the ticker symbol “ELAN.” The offering is expected to close on September 24, 2018, subject to customary closing conditions.
Sep 06, 2018 06:53 am ET
Elanco Announces Launch of IPO Roadshow
GREENFIELD, Ind., Sept. 6, 2018 /PRNewswire/ -- Elanco Animal Health Incorporated, a subsidiary of Eli Lilly and Company (NYSE:LLY), today announced it has launched a roadshow for the initial public offering (IPO) of its common stock. ...